Get the Stockscreener App
2.185
3.31%
0.07
Nautilus Biotechnology Inc stock is traded at $2.185, with a volume of 149.56K.
It is up +3.31% in the last 24 hours and up +53.87% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$2.115
Open:
$2.19
24h Volume:
149.56K
Relative Volume:
0.30
Market Cap:
$275.35M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-3.9018
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
+21.39%
1M Performance:
+53.87%
6M Performance:
+178.49%
1Y Performance:
-8.19%
1-Day Range:
$2.0665
$2.24
1-Week Range:
$1.80
$2.54
52-Week Range:
$0.62
$2.54
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.18 | 267.14M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.64 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.68 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.20 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.13 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.30 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
There is no way Nautilus Biotechnology Inc (NAUT) can keep these numbers up - Setenews
Advanced analytics toolkit walkthrough for Nautilus Biotechnology Inc.2025 Trading Recap & Precise Trade Entry Recommendations - newser.com
What dividend safety score for Nautilus Biotechnology Inc. stockMarket Growth Report & Low Volatility Stock Recommendations - newser.com
Long term hold vs stop loss in Nautilus Biotechnology Inc.Market Risk Summary & Daily Profit Focused Stock Screening - newser.com
Will Nautilus Biotechnology Inc. stock maintain momentum in 2025Recession Risk & Low Drawdown Investment Ideas - newser.com
Has Nautilus Biotechnology Inc. found a price floorMarket Growth Summary & Free High Accuracy Swing Entry Alerts - newser.com
What candlestick patterns are forming on Nautilus Biotechnology Inc.Weekly Trend Recap & Reliable Price Breakout Signals - newser.com
Will Nautilus Biotechnology Inc. stock outperform value stocksMarket Trend Summary & Reliable Volume Spike Trade Alerts - newser.com
Why Nautilus Biotechnology Inc. stock is recommended by analystsMarket Activity Summary & Risk Controlled Swing Trade Alerts - newser.com
Wall Street Zen Upgrades Nautilus Biotechnology (NASDAQ:NAUT) to Hold - Defense World
How to recover losses in Nautilus Biotechnology Inc. stockBull Run & Technical Entry and Exit Alerts - newser.com
Why Nautilus Biotechnology Inc. stock is considered a top pickMarket Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Nautilus Biotechnology Inc. stock oversold or undervaluedEarnings Overview Summary & Free High Return Stock Watch Alerts - newser.com
How Nautilus Biotechnology Inc. stock performs in rate cut cyclesPortfolio Update Report & Community Trade Idea Sharing Platform - newser.com
How geopolitical tensions affect Nautilus Biotechnology Inc. stock2025 Breakouts & Breakdowns & Real-Time Volume Triggers - newser.com
Published on: 2025-11-13 14:26:20 - newser.com
Strategies to average down on Nautilus Biotechnology Inc.Trade Entry Report & Weekly Stock Breakout Alerts - newser.com
Can Nautilus Biotechnology Inc. stock weather global recessionBuy Signal & High Conviction Buy Zone Alerts - newser.com
Suzuki Kentaro buys Nautilus Biotechnology shares worth $5,960 By Investing.com - Investing.com Canada
[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity - Stock Titan
Officer Suzuki Buys 4,000 ($6K) Of Nautilus Biotechnology Inc [NAUT] - TradingView
Wall Street Zen Downgrades Nautilus Biotechnology (NASDAQ:NAUT) to Sell - Defense World
Nautilus Biotechnology redefines proteomics at HUPO2025 - Traders Union
Is this a good reentry point in Nautilus Biotechnology Inc.Share Buyback & Precise Trade Entry Recommendations - newser.com
Nautilus announces installation, testing of its external field evaluation unit - MSN
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nautilus Biotechnology Inc Stock (NAUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Sujal M | CEO, President, and Secretary |
Sep 05 '25 |
Buy |
0.67 |
116,500 |
78,544 |
10,258,221 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
| Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
| Mowry Anna | CFO and Treasurer |
May 29 '25 |
Buy |
0.77 |
15,000 |
11,488 |
83,000 |
| Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
1.75%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):